Kiromic Biopharma, Inc.
DelistedCIK 1792581fmd_1T7QEBZXYQWVC9A4SNXQCE2BBAManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Dec 31, 2024, 24 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Research and development | 1 | 5 | 11 | 14 | 7 | 7 |
| Total operating expenses | 4 | 19 | 26 | 31 | 20 | 24 |
| Operating income | (4) | (19) | (26) | (31) | (20) | (24) |
| Interest expense | 0 | 0 | 0 | 0 | – | – |
| Other non-operating income (expense) | – | – | – | 0 | (1) | (3) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (4) | (19) | (26) | (35) | (21) | (27) |
| Net income to common shareholders | (4) | (20) | (26) | (35) | (23) | (34) |